Incyte Pharmaceuticals, Inc.

Incyte Genomics, Inc.

Incyte Corporation

Bayer Schering Pharma Ag

Susan G Stuart

Jeffrey J Seilhamer

Roger T Coleman

Janice K Au-Young

Phillip R Hawkins

Lynn E Murry

Karl J Guegler

Olga Bandman

Scott Michael Braxton

Dinh Diep

Jennifer L Hillman

Purvi Shah

Henry Yue

James Randall Gilmore

Benjamin Graeme Cocks

Laura L Stuve

Victoria Lee Cohan

John J Monahan

Hong Xu

Stephen Green

Steven Daniel

Andrea Georgina King

Beatrice Claudia Langton

Peter Bluford

Lorrine A Chao

The present invention provides a polynucleotide (hjak2) which identifies and encodes a novel human Jak2 kinase (HJAK2) which was expressed in the placenta. The present invention also provides for antisense molecules and oligomers designed from the nucleotide sequence or its antisense. The invention further provides genetically engineered expression vectors and host cells for the production of purified HJAK2 peptide, antibodies capable of binding to HJAK2, inhibitors which bind to HJAK2 and pharmaceutical compositions based on HJAK2 specific antibodies or inhibitors. The invention specifically provides for diagnostic assays based on altered hjak2 expression and which allow identification of such a condition. These assays utilize probes which comprise oligomers, fragments, or portions of hjak2 or its regulatory elements or antibodies specifically binding HJAK2.

Human Jak2 kinase

The present invention relates to a composition comprising a plurality of polynucleotide probes. The composition can be used as hybridizable array elements in a microarray. The present invention also relates to a method for selecting polynucleotide probes for the composition.

Compositions for the detection of blood cell and immunological response gene expression

The present invention provides nucleotide and amino acid sequences that identify and encode novel cellubrevins (cb). The present invention also provides for antisense molecules to the nucleotide sequences which encode cbs, expression vectors for the production of purified CBs, antibodies capable of binding specifically to CBs, hybridization probes or oligonucleotides for the detecting the induction of CB encoding nucleotide sequences, genetically engineered host cells for the expression of CBs, diagnostic tests for activated, inflamed or diseased cells and/or tissues based on CB-encoding nucleic acid molecules and antibodies capable of binding specifically to CBs.

Cellubrevin homologs

The present invention provides nucleotide and amino acid sequences that identify and encode a novel purinergic P receptor (PNR) expressed in human placenta. The present invention also provides for antisense molecules to the nucleotide sequences which encode PNR, expression vectors for the production of purified PNR, antibodies capable of binding specifically to PNR, hybridization probes or oligonucleotides for the detection of PNR-encoding nucleotide sequences, genetically engineered host cells for the expression of PNR, and diagnostic tests based on PNR-encoding nucleic acid molecules or antibodies produced against the polypeptide PNR.

Human purinergic P2U receptor

The invention provides cDNA which encode Ndr2-related proteins. It also provides for the use of the cDNAs, fragments, complements, and variants thereof and of the encoded proteins, portions thereof and antibodies thereto for diagnosis and treatment of cancer, particularly cancers of the intestine, breast, uterus, liver, brain, and kidney. The invention additionally provides expression vectors and host cells for the production of the proteins and a transgenic model system.

Ndr2-related proteins

The invention provides a human checkpoint kinase (hChk1) and polynucleotides which identify and encode hChk1. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating or preventing disorders associated with expression of hChk1.

Human checkpoint kinase

The present invention relates to polynucleotides comprising genes that regulate cell proliferation. The present invention also relates to a method for diagnosing or monitoring the treatment of a disease characterized by the altered expression of genes that regulate cell proliferation in a sample.

Detection of altered expression of genes regulating cell proliferation

The present invention provides nucleotide and amino acid sequences that identify and encode a novel chemokine (EEC) expressed in human eosinophil cells. The present invention also provides for antisense molecules to the nucleotide sequences which encode EEC, expression vectors for the production of purified EEC, antibodies capable of binding specifically to EEC, hybridization probes or oligonucleotides for the detection of EEC-encoding nucleotide sequences, genetically engineered host cells for the expression of EEC, diagnostic tests for chemokine activation based on EEC-encoding nucleic acid molecules and antibodies capable of binding specifically to the protein.

Chemokine expressed in eosinophils

Human JAK2 kinase

The invention provides a human Emr1-like G protein coupled receptor (EGPCR) and polynucleotides which identify and encode EGPCR. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating or preventing disorders associated with expression of EGPCR.

Human Emr1-like G protein coupled receptor

The present invention provides nucleotide and amino acid sequences that identify and encode a novel purinergic P.sub.U2 receptor (PNR) expressed in human placenta. The present invention also provides for antisense molecules to the nucleotide sequences which encode PNR, expression vectors for the production of purified PNR, antibodies capable of binding specifically to PNR, hybridization probes or oligonucleotides for the detection of PNR-encoding nucleotide sequences, genetically engineered host cells for the expression of PNR, and diagnostic tests based on PNR-encoding nucleic acid molecules or antibodies produced against the polypeptide PNR.

Polynucleotide encoding a novel purinergic P.sub.2U receptor

The present invention provides nucleotide and amino acid sequences that identify and encode a novel serpin (CAPE) expressed in human hypothalamus. The present invention also provides for antisense molecules to the nucleotide sequences which encode CAPE, expression vectors for the production of purified CAPE, antibodies capable for binding specifically to CAPE, hybridization probes or oligonucleotides for the detection of CAPE-encoding nucleotide sequences, genetically engineered host cells for the expression of Cape, a pharmaceutical composition containing biologically active CAPE, a diagnostic test based on CAPE-encoding nucleic acid molecules, and treatment methods comprising administration of biologically active CAPE.

Growing community of inventors

Montara, CA, United States of America

Susan G Stuart